secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001193125-22-216156
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q2 revenue $121.4M (-1% YoY); net income falls 58% to $8.7M
-------------------------------------------------------------------------

- Net revenue $121.4M vs $123.2M in Q2 2021; adjusted revenue up 3% excluding ReNu/NuCel.
- Net income $8.7M ($0.07 diluted EPS) vs $20.7M ($0.15) a year ago; Adjusted net income $11.3M.
- Advanced Wound Care rev $113.8M (+2%), Surgical & Sports Medicine $7.6M (-35%).
- PuraPly rev $69.4M (+84%); non-PuraPly $52.0M (-39%).
- FY2022 guidance: net revenue $465M-$490M; Adj. EBITDA $60M-$74M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312522216156/0001193125-22-216156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312522216156/d382521d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-216156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer